Perspectives on neuroprotective stroke therapy
Department of Neurology
Animals; Brain Ischemia; Clinical Trials as Topic; Humans; Neuroprotective Agents; Stroke
Biochemistry | Medicinal Chemistry and Pharmaceutics | Nervous System Diseases | Neurology
After years of setbacks, the perspective of neuroprotective stroke therapy has revived in light of recent study results. We outline in this review how a neuroprotective candidate drug should be developed, beginning with a thorough preclinical evaluation according to the STAIR (Stroke Therapy Academic Industry Roundtable) criteria. Assessing the safety of the candidate drug in the relatively straightforward Phase IIA would be the first step into clinical development. While advancing into Phase IIB, the implementation of a responder analysis, the use of a surrogate biomarker as well as the use of Bayesian methodology should be considered to increase the likelihood of seeing any therapeutic sign. Clinical development in Phase III should consider that previously used dichotomized endpoints appropriate for evaluation of thrombolytic drugs are likely to be insufficient for assessing efficacy of neuroprotective drugs. Detection of a clinically relevant shift in the outcome measure appears to be a more relevant approach for the type of drug that achieves a reduction and not a reverse of the ischaemic lesion.
DOI of Published Version
Biochem Soc Trans. 2006 Dec;34(Pt 6):1271-6. Link to article on publisher's site
Biochemical Society transactions
Schabitz, Wolf-Rudiger and Fisher, Marc, "Perspectives on neuroprotective stroke therapy" (2006). Neurology Publications and Presentations. 115.